Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12403868 | 0.84 | TUBB1 (0.44) | TAS1R3TAS1R1GALR2TUBB1LMNA | |
| SCHEMBL21790726 | 0.82 | TUBB4A (0.46) | TUBB1LMNARAB9A | |
| SCHEMBL21790579 | 0.76 | TDO2 (0.34) | LMNARAB9A | |
| SCHEMBL12963121 | 0.76 | ICMT (0.45) | TAS1R3TAS1R1GALR2TUBB1LMNA | |
| SCHEMBL21790441 | 0.75 | RAPGEF4 (0.35) | — | |
| SCHEMBL21790802 | 0.74 | PTGS2 (0.44) | TUBB1MAPK1HTT | |
| SCHEMBL1239663 | 0.74 | BCL6 (0.45) | TAS1R3TAS1R1GALR2TUBB1LMNA | |
| SCHEMBL23084860 | 0.73 | KDM4E (0.38) | LMNAMAPK1HTTRAB9A | |
| SCHEMBL12932934 | 0.73 | ICMT (0.44) | TUBB1LMNAMAPK1HTTRAB9A | |
| SCHEMBL20565356 | 0.73 | MEN1 (0.45) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | ESANEX INC (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071308-A1 | Benzene, Pyridine, and Pyridazine Derivatives | CDK4, P2RX4, MKI67 | TAS1R3 2363/4885TAS1R1 2317/4885GALR2 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.